Sosiho‑tang  ||| S:0 E:12 ||| CD
ameliorates  ||| S:12 E:24 ||| CD
cachexia‑related  ||| S:24 E:41 ||| CD
symptoms  ||| S:41 E:50 ||| NNS
in  ||| S:50 E:53 ||| IN
mice  ||| S:53 E:58 ||| NNS
bearing  ||| S:58 E:66 ||| VBG
colon  ||| S:66 E:72 ||| NN
26  ||| S:72 E:75 ||| CD
adenocarcinoma  ||| S:75 E:90 ||| NN
by  ||| S:90 E:93 ||| IN
reducing  ||| S:93 E:102 ||| VBG
systemic  ||| S:102 E:111 ||| JJ
inflammation  ||| S:111 E:124 ||| NN
and  ||| S:124 E:128 ||| CC
muscle  ||| S:128 E:135 ||| NN
loss  ||| S:135 E:140 ||| NN
Cachexia  ||| S:140 E:149 ||| NNS
accompanied  ||| S:149 E:161 ||| VBN
by  ||| S:161 E:164 ||| IN
muscle  ||| S:164 E:171 ||| NN
wasting  ||| S:171 E:179 ||| NN
is  ||| S:179 E:182 ||| VBZ
a  ||| S:182 E:184 ||| DT
key  ||| S:184 E:188 ||| JJ
determinant  ||| S:188 E:200 ||| NN
of  ||| S:200 E:203 ||| IN
poor  ||| S:203 E:208 ||| JJ
prognosis  ||| S:208 E:218 ||| NN
in  ||| S:218 E:221 ||| IN
cancer  ||| S:221 E:228 ||| NN
patients  ||| S:228 E:237 ||| NNS
and  ||| S:237 E:241 ||| CC
cancer‑related  ||| S:241 E:256 ||| CD
death ||| S:256 E:261 ||| NN
.  ||| S:261 E:263 ||| .
Previous  ||| S:263 E:272 ||| JJ
studies  ||| S:272 E:280 ||| NNS
have  ||| S:280 E:285 ||| VBP
demonstrated  ||| S:285 E:298 ||| VBN
that  ||| S:298 E:303 ||| IN
inflammatory  ||| S:303 E:316 ||| JJ
cytokines  ||| S:316 E:326 ||| JJ
such  ||| S:326 E:331 ||| JJ
as  ||| S:331 E:334 ||| IN
interleukin‑6  ||| S:334 E:348 ||| NNP
( ||| S:348 E:349 ||| -LRB-
IL‑6 ||| S:349 E:353 ||| NNP
) ||| S:353 E:354 ||| -RRB-
,  ||| S:354 E:356 ||| ,
tumor  ||| S:356 E:362 ||| FW
necrosis  ||| S:362 E:371 ||| FW
factor‑α  ||| S:371 E:380 ||| FW
( ||| S:380 E:381 ||| -LRB-
TNF‑α ||| S:381 E:386 ||| NNP
) ||| S:386 E:387 ||| -RRB-
,  ||| S:387 E:389 ||| ,
IL‑1  ||| S:389 E:394 ||| NNP
and  ||| S:394 E:398 ||| CC
interferon‑γ  ||| S:398 E:411 ||| NNP
( ||| S:411 E:412 ||| -LRB-
IFN‑γ ||| S:412 E:417 ||| NNP
)  ||| S:417 E:419 ||| -RRB-
secreted  ||| S:419 E:428 ||| NN
from  ||| S:428 E:433 ||| IN
host  ||| S:433 E:438 ||| NN
cells  ||| S:438 E:444 ||| NNS
and  ||| S:444 E:448 ||| CC
tumor  ||| S:448 E:454 ||| NN
cells  ||| S:454 E:460 ||| NNS
participate  ||| S:460 E:472 ||| VBP
in  ||| S:472 E:475 ||| IN
skeletal  ||| S:475 E:484 ||| JJ
muscle  ||| S:484 E:491 ||| NN
wasting  ||| S:491 E:499 ||| VBZ
followed  ||| S:499 E:508 ||| VBN
by  ||| S:508 E:511 ||| IN
severe  ||| S:511 E:518 ||| JJ
loss  ||| S:518 E:523 ||| NN
of  ||| S:523 E:526 ||| IN
body  ||| S:526 E:531 ||| NN
weight ||| S:531 E:537 ||| NN
.  ||| S:537 E:539 ||| .
Therefore ||| S:539 E:548 ||| RB
,  ||| S:548 E:550 ||| ,
blockade  ||| S:550 E:559 ||| NN
of  ||| S:559 E:562 ||| IN
the  ||| S:562 E:566 ||| DT
inflammatory  ||| S:566 E:579 ||| JJ
response  ||| S:579 E:588 ||| NN
is  ||| S:588 E:591 ||| VBZ
thought  ||| S:591 E:599 ||| VBN
to  ||| S:599 E:602 ||| TO
be  ||| S:602 E:605 ||| VB
a  ||| S:605 E:607 ||| DT
logical  ||| S:607 E:615 ||| JJ
target  ||| S:615 E:622 ||| NN
for  ||| S:622 E:626 ||| IN
pharmacological  ||| S:626 E:642 ||| NN
and  ||| S:642 E:646 ||| CC
nutritional  ||| S:646 E:658 ||| JJ
interventions  ||| S:658 E:672 ||| NNS
to  ||| S:672 E:675 ||| TO
preserve  ||| S:675 E:684 ||| VB
skeletal  ||| S:684 E:693 ||| JJ
muscle  ||| S:693 E:700 ||| NN
mass  ||| S:700 E:705 ||| NN
under  ||| S:705 E:711 ||| IN
cachectic  ||| S:711 E:721 ||| JJ
conditions ||| S:721 E:731 ||| NNS
.  ||| S:731 E:733 ||| .
Sosiho‑tang  ||| S:733 E:745 ||| NNP
( ||| S:745 E:746 ||| -LRB-
SO ||| S:746 E:748 ||| NNP
;  ||| S:748 E:750 ||| :
Xiaocharihu‑tang  ||| S:750 E:767 ||| CD
in  ||| S:767 E:770 ||| IN
Chinese  ||| S:770 E:778 ||| JJ
and  ||| S:778 E:782 ||| CC
Sho‑saiko‑to  ||| S:782 E:795 ||| CD
in  ||| S:795 E:798 ||| IN
Japanese ||| S:798 E:806 ||| JJ
)  ||| S:806 E:808 ||| -RRB-
is  ||| S:808 E:811 ||| VBZ
an  ||| S:811 E:814 ||| DT
Oriental  ||| S:814 E:823 ||| JJ
herbal  ||| S:823 E:830 ||| JJ
medicine  ||| S:830 E:839 ||| NN
that  ||| S:839 E:844 ||| WDT
has  ||| S:844 E:848 ||| VBZ
been  ||| S:848 E:853 ||| VBN
used  ||| S:853 E:858 ||| VBN
to  ||| S:858 E:861 ||| TO
treat  ||| S:861 E:867 ||| VB
chronic  ||| S:867 E:875 ||| JJ
hepatic  ||| S:875 E:883 ||| JJ
diseases  ||| S:883 E:892 ||| NNS
and  ||| S:892 E:896 ||| CC
to  ||| S:896 E:899 ||| TO
control  ||| S:899 E:907 ||| VB
fever ||| S:907 E:912 ||| NN
.  ||| S:912 E:914 ||| .
In  ||| S:914 E:917 ||| IN
recent  ||| S:917 E:924 ||| JJ
studies ||| S:924 E:931 ||| NNS
,  ||| S:931 E:933 ||| ,
SO  ||| S:933 E:936 ||| NNP
inhibited  ||| S:936 E:946 ||| VBD
the  ||| S:946 E:950 ||| DT
production  ||| S:950 E:961 ||| NN
of  ||| S:961 E:964 ||| IN
inflammatory  ||| S:964 E:977 ||| JJ
cytokines  ||| S:977 E:987 ||| NN
in  ||| S:987 E:990 ||| IN
lipopolysaccharide  ||| S:990 E:1009 ||| NNS
( ||| S:1009 E:1010 ||| -LRB-
LPS ||| S:1010 E:1013 ||| NNP
) ||| S:1013 E:1014 ||| -RRB-
‑stimulated  ||| S:1014 E:1026 ||| CD
macrophages ||| S:1026 E:1037 ||| NN
,  ||| S:1037 E:1039 ||| ,
prevented  ||| S:1039 E:1049 ||| VBD
thrombus  ||| S:1049 E:1058 ||| JJ
formation  ||| S:1058 E:1068 ||| NN
and  ||| S:1068 E:1072 ||| CC
suppressed  ||| S:1072 E:1083 ||| JJ
cancer  ||| S:1083 E:1090 ||| NN
progression ||| S:1090 E:1101 ||| NN
.  ||| S:1101 E:1103 ||| .
However ||| S:1103 E:1110 ||| RB
,  ||| S:1110 E:1112 ||| ,
the  ||| S:1112 E:1116 ||| DT
anti‑cachectic  ||| S:1116 E:1131 ||| JJ
activity  ||| S:1131 E:1140 ||| NN
of  ||| S:1140 E:1143 ||| IN
SO  ||| S:1143 E:1146 ||| NNP
in  ||| S:1146 E:1149 ||| IN
tumor‑bearing  ||| S:1149 E:1163 ||| CD
mice  ||| S:1163 E:1168 ||| NNS
has  ||| S:1168 E:1172 ||| VBZ
not  ||| S:1172 E:1176 ||| RB
yet  ||| S:1176 E:1180 ||| RB
been  ||| S:1180 E:1185 ||| VBN
examined ||| S:1185 E:1193 ||| VBN
.  ||| S:1193 E:1195 ||| .
In  ||| S:1195 E:1198 ||| IN
the  ||| S:1198 E:1202 ||| DT
present  ||| S:1202 E:1210 ||| JJ
study ||| S:1210 E:1215 ||| NN
,  ||| S:1215 E:1217 ||| ,
we  ||| S:1217 E:1220 ||| PRP
characterized  ||| S:1220 E:1234 ||| VBD
the  ||| S:1234 E:1238 ||| DT
effect  ||| S:1238 E:1245 ||| NN
of  ||| S:1245 E:1248 ||| IN
SO  ||| S:1248 E:1251 ||| NNP
administration  ||| S:1251 E:1266 ||| NN
on  ||| S:1266 E:1269 ||| IN
cancer‑induced  ||| S:1269 E:1284 ||| CD
cachexia  ||| S:1284 E:1293 ||| NN
in  ||| S:1293 E:1296 ||| IN
CT‑26‑bearing  ||| S:1296 E:1310 ||| CD
mice ||| S:1310 E:1314 ||| NNS
,  ||| S:1314 E:1316 ||| ,
and  ||| S:1316 E:1320 ||| CC
elucidated  ||| S:1320 E:1331 ||| VBG
the  ||| S:1331 E:1335 ||| DT
anti‑cachectic  ||| S:1335 E:1350 ||| CD
mechanisms ||| S:1350 E:1360 ||| NNS
.  ||| S:1360 E:1362 ||| .
Daily  ||| S:1362 E:1368 ||| JJ
oral  ||| S:1368 E:1373 ||| JJ
administration  ||| S:1373 E:1388 ||| NN
of  ||| S:1388 E:1391 ||| IN
SO  ||| S:1391 E:1394 ||| NNP
at  ||| S:1394 E:1397 ||| IN
doses  ||| S:1397 E:1403 ||| NNS
of  ||| S:1403 E:1406 ||| IN
50 and 100 mg ||| S:1406 E:1419 ||| CD
/ ||| S:1419 E:1420 ||| CD
kg  ||| S:1420 E:1423 ||| NN
to  ||| S:1423 E:1426 ||| TO
CT‑26‑bearing  ||| S:1426 E:1440 ||| CD
mice  ||| S:1440 E:1445 ||| NNS
significantly  ||| S:1445 E:1459 ||| RB
retarded  ||| S:1459 E:1468 ||| JJ
tumor  ||| S:1468 E:1474 ||| NN
growth  ||| S:1474 E:1481 ||| NN
and  ||| S:1481 E:1485 ||| CC
prevented  ||| S:1485 E:1495 ||| VBD
the  ||| S:1495 E:1499 ||| DT
loss  ||| S:1499 E:1504 ||| NN
of  ||| S:1504 E:1507 ||| IN
final  ||| S:1507 E:1513 ||| JJ
body  ||| S:1513 E:1518 ||| NN
weight ||| S:1518 E:1524 ||| NN
,  ||| S:1524 E:1526 ||| ,
carcass  ||| S:1526 E:1534 ||| JJ
weight ||| S:1534 E:1540 ||| NN
,  ||| S:1540 E:1542 ||| ,
heart  ||| S:1542 E:1548 ||| NN
weight ||| S:1548 E:1554 ||| NN
,  ||| S:1554 E:1556 ||| ,
gastrocnemius  ||| S:1556 E:1570 ||| JJ
muscle ||| S:1570 E:1576 ||| NN
,  ||| S:1576 E:1578 ||| ,
and  ||| S:1578 E:1582 ||| CC
epididymal  ||| S:1582 E:1593 ||| JJ
fat ||| S:1593 E:1596 ||| NN
,  ||| S:1596 E:1598 ||| ,
compared  ||| S:1598 E:1607 ||| VBN
with  ||| S:1607 E:1612 ||| IN
saline‑treated  ||| S:1612 E:1627 ||| CD
control  ||| S:1627 E:1635 ||| NN
mice ||| S:1635 E:1639 ||| NNS
.  ||| S:1639 E:1641 ||| .
In  ||| S:1641 E:1644 ||| IN
addition ||| S:1644 E:1652 ||| NN
,  ||| S:1652 E:1654 ||| ,
serum  ||| S:1654 E:1660 ||| CD
IL‑6  ||| S:1660 E:1665 ||| CD
levels  ||| S:1665 E:1672 ||| NNS
elevated  ||| S:1672 E:1681 ||| VBD
by  ||| S:1681 E:1684 ||| IN
cancer  ||| S:1684 E:1691 ||| NN
were  ||| S:1691 E:1696 ||| VBD
decreased  ||| S:1696 E:1706 ||| VBN
by  ||| S:1706 E:1709 ||| IN
SO  ||| S:1709 E:1712 ||| NNP
administration ||| S:1712 E:1726 ||| NN
.  ||| S:1726 E:1728 ||| .
In  ||| S:1728 E:1731 ||| IN
the  ||| S:1731 E:1735 ||| DT
J774A.1  ||| S:1735 E:1743 ||| JJ
macrophage  ||| S:1743 E:1754 ||| JJ
cell  ||| S:1754 E:1759 ||| NN
line ||| S:1759 E:1763 ||| NN
,  ||| S:1763 E:1765 ||| ,
SO  ||| S:1765 E:1768 ||| FW
efficiently  ||| S:1768 E:1780 ||| FW
suppressed  ||| S:1780 E:1791 ||| FW
LPS‑mediated  ||| S:1791 E:1804 ||| FW
increases  ||| S:1804 E:1814 ||| FW
in  ||| S:1814 E:1817 ||| FW
inducible  ||| S:1817 E:1827 ||| FW
nitric  ||| S:1827 E:1834 ||| FW
oxide  ||| S:1834 E:1840 ||| FW
synthase  ||| S:1840 E:1849 ||| FW
( ||| S:1849 E:1850 ||| -LRB-
iNOS ||| S:1850 E:1854 ||| NNP
)  ||| S:1854 E:1856 ||| -RRB-
expression ||| S:1856 E:1866 ||| NN
,  ||| S:1866 E:1868 ||| ,
nitric  ||| S:1868 E:1875 ||| JJ
oxide  ||| S:1875 E:1881 ||| NN
( ||| S:1881 E:1882 ||| -LRB-
NO ||| S:1882 E:1884 ||| UH
) ||| S:1884 E:1885 ||| -RRB-
,  ||| S:1885 E:1887 ||| ,
and  ||| S:1887 E:1891 ||| CC
procachectic  ||| S:1891 E:1904 ||| JJ
inflammatory  ||| S:1904 E:1917 ||| JJ
cytokine  ||| S:1917 E:1926 ||| JJ
production  ||| S:1926 E:1937 ||| NN
through  ||| S:1937 E:1945 ||| IN
inhibition  ||| S:1945 E:1956 ||| NN
of  ||| S:1956 E:1959 ||| IN
nuclear  ||| S:1959 E:1967 ||| JJ
factor‑κB  ||| S:1967 E:1977 ||| NNP
( ||| S:1977 E:1978 ||| -LRB-
NF‑κB ||| S:1978 E:1983 ||| NNP
)  ||| S:1983 E:1985 ||| -RRB-
and  ||| S:1985 E:1989 ||| CC
p38  ||| S:1989 E:1993 ||| CD
activation ||| S:1993 E:2003 ||| NNS
.  ||| S:2003 E:2005 ||| .
In  ||| S:2005 E:2008 ||| IN
addition ||| S:2008 E:2016 ||| NN
,  ||| S:2016 E:2018 ||| ,
SO  ||| S:2018 E:2021 ||| NNP
attenuated  ||| S:2021 E:2032 ||| JJ
muscle  ||| S:2032 E:2039 ||| NN
atrophy  ||| S:2039 E:2047 ||| VBZ
caused  ||| S:2047 E:2054 ||| VBN
by  ||| S:2054 E:2057 ||| IN
cancer  ||| S:2057 E:2064 ||| NN
cells  ||| S:2064 E:2070 ||| NNS
by  ||| S:2070 E:2073 ||| IN
affecting  ||| S:2073 E:2083 ||| VBG
myoblast  ||| S:2083 E:2092 ||| JJ
proliferation  ||| S:2092 E:2106 ||| NN
and  ||| S:2106 E:2110 ||| CC
differentiation ||| S:2110 E:2125 ||| NN
,  ||| S:2125 E:2127 ||| ,
and  ||| S:2127 E:2131 ||| CC
C2C12  ||| S:2131 E:2137 ||| CD
myotube  ||| S:2137 E:2145 ||| JJ
wasting ||| S:2145 E:2152 ||| NN
.  ||| S:2152 E:2154 ||| .
Taken  ||| S:2154 E:2160 ||| VBN
together ||| S:2160 E:2168 ||| RB
,  ||| S:2168 E:2170 ||| ,
these  ||| S:2170 E:2176 ||| DT
results  ||| S:2176 E:2184 ||| NNS
suggest  ||| S:2184 E:2192 ||| VBP
that  ||| S:2192 E:2197 ||| IN
SO  ||| S:2197 E:2200 ||| NNP
is  ||| S:2200 E:2203 ||| VBZ
a  ||| S:2203 E:2205 ||| DT
safe  ||| S:2205 E:2210 ||| JJ
and  ||| S:2210 E:2214 ||| CC
useful  ||| S:2214 E:2221 ||| JJ
anti‑cachectic  ||| S:2221 E:2236 ||| CD
therapy  ||| S:2236 E:2244 ||| NN
for  ||| S:2244 E:2248 ||| IN
cancer  ||| S:2248 E:2255 ||| NN
patients  ||| S:2255 E:2264 ||| NNS
with  ||| S:2264 E:2269 ||| IN
severe  ||| S:2269 E:2276 ||| JJ
weight  ||| S:2276 E:2283 ||| NN
loss ||| S:2283 E:2287 ||| NN
.  ||| S:2287 E:2289 ||| .
